← back to search

Nathalie Y.R. Agar

Harvard University · US
Area of research
Genetics · Cancer Research
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, ATP Synthase and ATPases Research, and Mass Spectrometry Techniques and Applications.
h-index
50
citations
9,133
works
410
NIH funding
primary concept
Medicine
email

Recent publications

Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression
Cancer Cell 2026cited by 4position: middledoi
Rewiring of cortical glucose metabolism fuels human brain cancer growth
Nature 2025cited by 27position: middledoi
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Science Translational Medicine 2025cited by 13position: middledoi
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Science Translational Medicine 2025cited by 10position: middledoi
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma
Clinical Cancer Research 2025cited by 6position: middledoi
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Nature Metabolism 2025cited by 1position: middledoi
TMIC-70. Integrative spatiotemporal proteomic and metabolomic characterization of immune infiltration following intracranial injection of oncolytic immunotherapy in glioblastoma patients
Neuro-Oncology 2025cited by 0position: lastdoi
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Neuro-Oncology 2024cited by 18position: middledoi
Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS
PLoS Biology 2024cited by 10position: middledoi
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Cancer Discovery 2023cited by 143position: middledoi
Oncometabolite <scp>d</scp> -2HG alters T cell metabolism to impair CD8 <sup>+</sup> T cell function
Science 2022cited by 268position: middledoi
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Cancer Cell 2022cited by 128position: middledoi
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Cancer Discovery 2022cited by 62position: middledoi
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Cell Reports 2022cited by 55position: middledoi
LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study
Neuro-Oncology 2022cited by 25position: middledoi
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Neuro-Oncology 2021cited by 79position: middledoi
Multimodal platform for assessing drug distribution and response in clinical trials
Neuro-Oncology 2021cited by 13position: lastdoi
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Journal of Clinical Oncology 2019cited by 153position: middledoi
Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma
Cancer Research 2019cited by 97position: lastdoi
Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data
Analytical Chemistry 2019cited by 56position: lastdoi
Blood–brain-barrier organoids for investigating the permeability of CNS therapeutics
Nature Protocols 2018cited by 275position: middledoi
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
Nature Communications 2018cited by 78position: lastdoi
Rapid discrimination of pediatric brain tumors by mass spectrometry imaging
Journal of Neuro-Oncology 2018cited by 57position: middledoi
Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Neuro-Oncology 2017cited by 688position: middledoi
Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents
Nature Communications 2017cited by 332position: middledoi
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma
Cancer Cell 2017cited by 220position: middledoi
Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling
Cell Communication and Signaling 2017cited by 42position: middledoi
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Proceedings of the National Academy of Sciences 2014cited by 258position: lastdoi
Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis
Proceedings of the National Academy of Sciences 2014cited by 244position: lastdoi
ET-24 * A NOVEL TROJAN HORSE FOR IN-VIVO SENSITIVITY TESTING OF MEDULLOBLASTOMA THERAPIES
Neuro-Oncology 2014cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sandro Santagata · Harvard University10 papers (2013–2025) · 6 papers (2014–2018)Michael S. Regan · Harvard University6 papers (2018–2025) · 5 papers (2022–2026) · 5 papers (2013–2014)Jeffrey N. Agar · Northeastern University4 papers (2013–2019)Keith L. Ligon · Harvard University4 papers (2013–2025)Jann N. Sarkaria · The University of Texas Southwestern Medical Center4 papers (2017–2024)Alexandra J. Golby · New York University4 papers (2013–2022)Daniel A. Orringer · NYU Langone Health3 papers (2013–2014)Xiaohui Liu · Fudan University3 papers (2013–2014) · 3 papers (2013–2014)Sean Lawler · Brown University3 papers (2017–2019)Jennifer Gantchev · McGill University Health Centre3 papers (2025–2026) · 3 papers (2013–2014)Marcia C. Haigis · Harvard University2 papers (2019–2022)Sylwia A. Stopka · Harvard University2 papers (2022–2022) · 2 papers (2013–2014) · 2 papers (2019–2019)Justin M. Wolfe · Massachusetts Institute of Technology2 papers (2017–2018)